Component evidence does not prove the NanoACi protocol

The distinction that matters before reading any component paper

A clinician reading the published literature on auricular cartilage micrografts, collagen scaffolds or platelet-rich fibrin will find genuine, peer-reviewed data. The instinct to add those bodies of evidence together — and conclude that a technique built from all three must therefore work — is understandable. It is also, by the standards of clinical evidence hierarchy, incorrect.

NanoACi is Professor Paul Lee's surgeon-led, non-arthroscopic, needle-delivered, one-stage autologous chondrogenic injection technique. It combines three biologically distinct roles in a single planned outpatient procedure: Seed (autologous auricular cartilage micrografts), Scaffold (a cell-free native type I collagen matrix), and Signal (autologous platelet-rich fibrin). Each component carries its own published evidence base. What does not yet exist is a randomised controlled trial — or a published prospective series — evaluating the exact three-part combination as a complete intervention.

That gap is not an oversight. NanoACi 100, the designated prospective outcomes programme, is designed to build precisely that body of evidence. Until its findings are published, the combined protocol is, in its founder's own words, 'a rationally designed technique, built entirely from individually evidenced parts.'

The distinction between 'evidence for each part' and 'proof of the combination' is not semantic caution — it is the clinical-reasoning principle embedded in how evidence hierarchies work, and it determines what any component paper can, and cannot, legitimately be taken to show.

How clinical evidence hierarchies rank combined protocols

Clinical evidence hierarchies exist for a specific reason: different study designs are differentially susceptible to bias and confounding. At the apex sit meta-analyses of randomised controlled trials, where random allocation and pooled analysis reduce systematic error. Descending through systematic reviews, single RCTs, cohort studies and case series, that susceptibility increases. At the base sit mechanistic reasoning and rationally designed technique experience — indispensable for generating hypotheses and designing interventions, but not for confirming that a specific combination produces specific outcomes in a defined patient population.

The structure is not punitive toward innovation. A technique occupying a lower tier is being honestly located, not dismissed.

For any multimodal protocol, the hierarchy applies a further principle: the combination is treated as a single clinical intervention. Component trials — however large or rigorous — do not aggregate upward into evidence for the procedure as a whole. The biological rationale for assembling individually evidenced parts is one category of knowledge; the measured clinical outcome of delivering them together, in sequence, to a defined population is another. The first answers 'why might this work?'; the second answers 'does it work, and for whom?' Both carry genuine clinical weight, and conflating them distorts the picture for patients and for the technique alike.

NanoACi currently has a well-supported answer to the first question. The sections that follow examine what each component's evidence actually shows — and precisely where each body of research stops.

What the component evidence actually establishes

Three separate bodies of literature underpin the NanoACi design — one for each biological role. Their strength and character differ considerably, and those differences matter.

Seed — auricular cartilage micrografts

The micrografting evidence is the most directly applicable to the cellular step. Marcarelli et al. (Journal of Clinical Medicine, 2021;10(2):322) reported improved patient-reported quality of life and measurable MRI cartilage thickness at three years in a small cohort treated with auricular cartilage micrografts for knee chondropathy. Tsoukas et al. (Bioengineering, 2023;10(11):1294) found reductions in pain and improvements in function after a single intra-articular micrograft application in patients with early-to-moderate knee osteoarthritis. Both studies concern the Seed step in isolation. Mytocel MSK — a standalone micrografting injection — is positioned as the cell component alone; its clinical data describes that single step, not the full NanoACi protocol.

Scaffold — ChondroFiller (cell-free type I collagen matrix)

ChondroFiller carries RCT-level evidence against microfracture and more than a decade of clinical use across multiple joints. This represents the strongest evidence tier among the three components. It characterises the scaffold in isolation or, at most, in two-part combinations with regenerative cells — not in the three-part NanoACi sequence.

Signal — ArthroZheal autologous PRF

Platelet-rich fibrin carries biological credentials as a sustained source of growth-factor signalling. This is mechanistic and biological-rationale evidence — a different category from the clinical-outcome data supporting the Seed and Scaffold, though a legitimate foundation for inclusion in the protocol design.

What these bodies of evidence collectively mean

Taken together, they provide the rational biological justification for assembling NanoACi as it stands. Component evidence suggests why each element belongs; it does not, individually or in aggregate, constitute outcome evidence for the combined three-part procedure.

Why combination creates an emergent system, not a sum

Separately evidenced parts do not sum into a proven combination. The reason is biological, not merely bureaucratic.

When auricular micrografts, a collagen scaffold and autologous PRF are delivered together in a defined sequence, each element enters an environment already shaped by the others. The PRF signalling milieu influences micrograft behaviour; scaffold architecture affects the distribution and retention of those cells; the concentration and timing of growth-factor release from fibrin interact with early cellular activity in the graft. These are not three parallel trials happening simultaneously in one joint — they are one system with interdependencies that no single-component study was designed to characterise.

Published evidence exists for pairing a collagen scaffold with regenerative cells, including in clinically demanding presentations. That two-component finding is meaningful, but it describes a different intervention from the full three-part NanoACi combination. Substituting it as proxy evidence for the complete protocol would be a category error: the third element — PRF as both medium and signal — changes the biological environment for the other two.

Professor Lee frames the current position plainly: NanoACi is 'a rationally designed technique, built entirely from individually evidenced parts' — and the distinction between rational design and proven combination outcome is precisely the gap NanoACi 100 is created to close.

The same non-extrapolation principle is applied without modification to NanoALi, the ligament analogue. That consistency is the marker of principled clinical governance, not selective modesty about cartilage repair specifically.

Where NanoACi sits on the evidence hierarchy right now

For clinicians, the evidence position of NanoACi as of September 2026 has a precise name: rationally designed, component-evidenced, combined-protocol outcomes in prospective development. That is a clearly defined location on the hierarchy — not an absence of clinical rigour, and not a position that can be upgraded by appealing to the strength of individual components.

No RCT or large prospective series covers the exact three-part combination. That gap is not unusual for a novel multimodal technique at this stage of its development; what distinguishes NanoACi is that the gap is acknowledged explicitly, governed formally, and being closed through a designated programme. NanoACi 100 is the prospective outcomes cohort created to generate combined-technique evidence; no milestone, success rate or recovery timeline from that programme is yet published, and none should be cited until the data exist.

The approved formulation — 'Component evidence is available; combined-protocol outcomes are being developed through NanoACi 100' — is precise for a reason. It allows clinical partners and patients to hold two things simultaneously: that each biological element is supported by published evidence, and that the combination as a single clinical procedure has not yet been evaluated in a comparative trial. Neither half of that statement should be omitted.

Communicating this position accurately to patients is itself a clinical responsibility. Overstating the evidence base erodes trust if the technique is later scrutinised; understating the biological rationale does a disservice to the rational design. The governed transparency built into NanoACi's evidence architecture is intended to make that communication straightforward.

Holding both things simultaneously: a clinical reading guide

Two distinct questions face any clinician considering NanoACi for a patient: is the biological rationale sound? and has the combined protocol been evaluated as an intervention? The component papers answer the first convincingly; they do not touch the second. Holding that difference clearly is the practical reading discipline the evidence architecture demands.

When a patient asks 'is there evidence for this?', the honest answer has two parts. The components — micrografts, collagen scaffold, PRF — each carry published human or mechanistic evidence supporting their individual roles. The combined three-part protocol, delivered in the NanoACi sequence, has not yet been evaluated in a comparative trial; that work is the explicit purpose of NanoACi 100. Both halves of the answer are clinically useful, and both are true simultaneously; omitting either one misrepresents the current position.

Suitability is a separate and equally important discipline, and the two should not be conflated. NanoACi is a non-arthroscopic route for appropriate patients — not a universal replacement for ACI, MACI, or open surgery. Alignment, instability, mechanical pathology, symptom profile, and individual patient goals all bear on whether this lane is the right one. Individual suitability rests on specialist assessment and imaging review, not on published component indications read in isolation.

For clinicians advising patients now, the practical obligation is to hold the question open rather than close it prematurely. NanoACi 100 is the prospective programme designed to answer the combination question; when its data are published, the evidentiary position will move. Until then, the accurate and sufficient clinical account is: component rationale established, combined-protocol outcomes in prospective development — a distinction that, when stated plainly, both respects the available evidence and gives patients a clear view of what is known and what is still being measured.

1. [1] Hierarchy of Evidence. https://en.wikipedia.org/?curid=4521155 https://en.wikipedia.org/?curid=4521155
2. [2] Evidence-Based Medicine. https://en.wikipedia.org/?curid=10013 https://en.wikipedia.org/?curid=10013